Chiasma, Inc. (CHMA)
CHMAPrice: $3.76
Fair Value: 🔒
🔒score
Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the... more
Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medicatio... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Raj Kannan |
| IPO Date | 2015-07-16 | CAGR | -0.45% |
| Employees | 84 | Website | www.chiasma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CHMA chart loading...
Fundamentals
Technicals
| Enterprise Value | $172.09M | P/E Ratio | -2.39 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 2.14 |
| P/CF Ratio | -2.61 | P/FCF Ratio | — |
| EPS | $-1.57 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | 0.94% |
| Operating Margin | -63.88% | Profit Margin | -67.61% |
| ROE | -0.84% | ROA | -0.42% |
| ROCE | -0.44% | Current Ratio | 9.17 |
| Quick Ratio | 8.51 | Cash Ratio | 0.92 |
| Debt/Equity | — | Interest Coverage | -12.03 |
| Altman Z Score | — | Piotroski Score | — |